Oligometastatic hormone-sensitive Prostate Cancer – APCCC
Advanced Prostate Cancer Consensus Conference (APCCC) shared a post on X about a recent paper by Jun Gong et al. titled “Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer” published in ACS Journal Cancer.
Authors: Jun Gong, Jessica L. Janes, Claire Trustram Eve, Shannon Stock, Justin Waller, Amanda M. De Hoedt, Jeri Kim, Sameer R. Ghate, Irene M. Shui, Stephen J. Freedland
“Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive Prostate Cancer out on ACS Journal Cancer.
Study analyzed the epidemiology, clinical outcomes, and treatment patterns of de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) within the U.S. Veterans Affairs Health Care System, focusing on patients diagnosed between 2015 and 2020.
Among 400 randomly selected patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC), 20% were identified as oligometastatic, defined as having five or fewer metastases (excluding the liver).
The study found that omHSPC patients had significantly better overall survival (OS) and castration-resistant prostate cancer (CRPC)-free survival compared to non-oligometastatic patients, with median OS of 44.4 months versus 26.2 months, respectively.
Despite better outcomes, the use of potentially curative therapies was still relatively low in omHSPC patients, indicating a need for further research into the benefits of multimodal therapy approaches.”
Bárbara Melão, Urologist in Uromed Manaus, shared this post, adding:
“Oligometastatic patients Prostate Cancer.
- 20% of mHSPC
- Only 14% received MDT/prostate RT
We should do better with a multimodal approach since we can achieve prolonged responses.”
Sources: APCCC/X and Bárbara Melão/X